Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Rithm Capital Corp. RITM

Alternate Symbol(s):  RITM.P.B

New Residential Investment Corp is a real estate investment trust that invests and manages investments related to residential real estate in the United States. The company's asset portfolio is mainly comprised of servicing-related assets and residential securities and loans. The vast majority of the cumulative outstanding face value of New Residential's portfolio is made up of excess mortgage servicing rights, or MSRs. The company collects interest income from these when the fee paid for an MSR exceeds the basic amount. Mortgage servicer advances, or loans extended to cover payments missed by homeowners, represent the majority of the carrying value of New Residential's investment portfolio. Most of these securities have short- to medium-term lifespans.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NYSE:RITM)

Fundamentals Snapshot (NYSE:RITM)

Opinion & Analysis (NYSE:RITM)

No current opinion is available.

Bullboard Posts (NYSE:RITM)

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
Eevhie - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >> FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets...
Eevhie - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
Eevhie - June 1, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

 
Eevhie - May 10, 2022

Lucid-MS for Multiple Sclerosis Treatment

<< View Post To Watch Video >>
Eevhie - May 1, 2022

"Julia Levy Award" Recipient David Allan and Dr. John McGraw

 
Eevhie - April 24, 2022